Glycation End Products, Advanced
"Glycation End Products, Advanced" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous group of compounds derived from rearrangements, oxidation, and cross-linking reactions that follow from non-enzymatic glycation of amino groups in proteins. They are also know as Maillard products. Their accumulation in vivo accelerates under hyperglycemic, oxidative, or inflammatory conditions. Heat also accelerates the formation of advanced glycation end products (AGEs) such seen with the browning of food during cooking under or over high heat.
| Descriptor ID |
D017127
|
| MeSH Number(s) |
D12.776.643.500
|
| Concept/Terms |
Glycation End Products, Advanced- Glycation End Products, Advanced
- Maillard Reaction End Products
- Maillard Reaction Products
- Products, Maillard Reaction
- Reaction Products, Maillard
- Advanced Maillard Reaction End Products
- Glycation Endproducts, Advanced
- Endproducts, Advanced Glycation
- Glycosylation End Products, Advanced
- Advanced Glycosylation Endproducts
- Endproducts, Advanced Glycosylation
- Glycosylation Endproducts, Advanced
- Advanced Glycation End Products
- Advanced Glycosylation End Products
- Maillard Products
- Products, Maillard
- Advanced Glycation Endproducts
|
Below are MeSH descriptors whose meaning is more general than "Glycation End Products, Advanced".
Below are MeSH descriptors whose meaning is more specific than "Glycation End Products, Advanced".
This graph shows the total number of publications written about "Glycation End Products, Advanced" by people in this website by year, and whether "Glycation End Products, Advanced" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 2 | 2 |
| 2012 | 2 | 1 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glycation End Products, Advanced" by people in Profiles.
-
Plasma AGE and Oxidation Products, Renal Function, and Preeclampsia in Pregnant Women with Type 1 Diabetes: A Prospective Observational Study. J Diabetes Res. 2023; 2023:8537693.
-
Identification of 2-benzoxazolinone derivatives as lead against molecular targets of diabetic complications. Chem Biol Drug Des. 2018 12; 92(6):1981-1987.
-
Characterization of IL-22 and antimicrobial peptide production in mice protected against pulmonary Cryptococcus neoformans infection. Microbiology (Reading). 2014 Jul; 160(Pt 7):1440-1452.
-
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab. 2013 May 07; 17(5):695-708.
-
Angiogenesis impairment in diabetes: role of methylglyoxal-induced receptor for advanced glycation endproducts, autophagy and vascular endothelial growth factor receptor 2. PLoS One. 2012; 7(10):e46720.
-
Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes. BJOG. 2012 Nov; 119(12):1512-20.
-
Oxidative and endoplasmic reticulum stresses mediate apoptosis induced by modified LDL in human retinal Müller cells. Invest Ophthalmol Vis Sci. 2012 Jul 09; 53(8):4595-604.
-
N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: a clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients. Am J Ther. 2009 Nov-Dec; 16(6):517-33.
-
State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases. Curr Clin Pharmacol. 2009 Jan; 4(1):4-37.
-
Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009 Feb; 94(2):410-5.